Home/Pipeline/Cryo-ablation Therapy for Obesity

Cryo-ablation Therapy for Obesity

Obesity

Pre-clinicalActive

Key Facts

Indication

Obesity

Phase

Pre-clinical

Status

Active

Company

Sedivention

About Sedivention

Sedivention is a Munich-based, privately-held medical device startup pioneering a novel interventional weight-loss therapy. The company's core technology is a cryo-ablation catheter designed to disrupt the gastric vagal nerve trunks in a brief, one-time procedure, aiming to deliver long-term reduction of hunger. Founded in 2021 (with roots from 2016), the company is in the pre-clinical/early development stage, backed by grants and venture capital, and is actively building its network and commercial strategy for future clinical and regulatory milestones.

View full company profile

Therapeutic Areas

Obesity

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active